// App-Quantinova.ai

Tu1327a : Golimumab for Treatment of Moderate to Severe Anti-TNF Refaractory Crohn's Disease: Open Label Experience

Researchers

Presenter

  • Anna Iacono

Principal Investigators

  • Sue P. Irwin

  • Mark S. Silverberg

  • Gordon R. Greenberg

Medical Centers

  • University of Toronto, Toronto, ON, Canada

  • Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

  • Crohn's disease

  • Inflammatory Arthritis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Certolizumab pegol

  • Ustekinumab

  • Adalimumab

  • Infliximab

  • Budesonide

  • Prednisone

  • golimumab

Outcome

  • N/A

Study Design

  • open label

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved